Healthcare entity
Each story carries 47.7 original sources on average, compared with 4.3 for the broader beat in this window. At 7.7, the average consequence score sits above the same-window beat average of 6.2. Amgen is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Each story carries 47.7 original sources on average, compared with 4.3 for the broader beat in this window. At 7.7, the average consequence score sits above the same-window beat average of 6.2. Amgen is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. The 127-day window averages about 0.2 stories each week. The clearest coverage concentration is acquisition: 1 of 3 stories, with the rest divided among 2 other categories. We currently track 3 Healthcare stories that mention Merck, published between March 12, 2026 and July 16, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 490 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Source: abcnews.com · clickorlando.com
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Merck is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
